Mechanisms of glucocorticoid signalling.

AMC Liver Center, Academic Medical Center, University of Amsterdam, Meibergdreef 69-71, 1105 BK, Amsterdam, The Netherlands.
Biochimica et Biophysica Acta (Impact Factor: 4.66). 11/2004; 1680(2):114-28. DOI: 10.1016/j.bbaexp.2004.09.004
Source: PubMed

ABSTRACT It has become increasingly clear that glucocorticoid signalling not only comprises the binding of the glucocorticoid receptor (GR) to its response element (GRE), but also involves indirect regulation glucocorticoid-responsive genes by regulating or interacting with other transcription factors. In addition, they can directly regulate gene expression by binding to negative glucocorticoid response elements (nGREs), to simple GREs, to GREs, or to GREs and GRE half sites (GRE1/2s) that are part of a regulatory unit. A response unit allows a higher level of glucocorticoid induction than simple GREs and, in addition, allows the integration of tissue-specific information with the glucocorticoid response. Presumably, the complexity of such a glucocorticoid response unit (GRU) depends on the number of pathways that integrate at this unit. Because GRUs are often located at distant sites relative to the transcription-start site, the GRU has to find a way to communicate with the basal-transcription machinery. We propose that the activating signal of a distal enhancer can be relayed onto the transcription-initiation complex by coupling elements located proximal to the promoter.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Protein ubiquitination can be reversed by de-ubiquitinating enzymes (DUBs), which are classified into two main classes, cysteine proteases and metalloproteases. Cysteine proteases include ubiquitin-specific proteases (USPs) and ubiquitin C-terminal hydrolases. USP22 is a USP family member and a component of the mammalian SAGA transcriptional co-activating complex. Regulator of calcineurin 1 (RCAN1; also known as DSCR1 or MCIP1) functions as an endogenous inhibitor of calcineurin signaling. In the present study, we have identified a novel interaction between USP22 and RCAN1 (RCAN1-1S) in the mammalian cells. In addition, the overexpression of USP22 caused the increase of RCAN1 protein stability. USP22 antagonized the actions of FBW7, NEDD4-2, and β-TrCP E3 ligase on RCAN1 and promoted RCAN1 de-ubiquitination. Moreover, we found that RCAN1 was bound to USP22 in basal conditions, and interferon-α (IFN-α) treatment caused the dissociation of RCAN1 from USP22, which subsequently triggered RCAN1 ubiquitination and proteasome degradation. Taken together, these results suggest that USP22 positively regulates RCAN1 levels, which would consequently affect diverse RCAN1-linked cellular processes such as the inflammatory process involving the release of IFN-α. This article is protected by copyright. All rights reserved
    Journal of Cellular Physiology 12/2014; 230(7). DOI:10.1002/jcp.24917 · 3.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Pseudomyxoma peritonei (PMP) is a rare neoplastic disease characterized by dissemination of mucinous tumor implants and accumulation of mucin in the abdominopelvic cavity. PMP is a progressive, recurrent condition that dramatically impacts quality of life. The current standard of care includes cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC).Areas covered: The clinicopathological features of PMP closely correspond with multifocal distribution of mucin-secreting tumors and mucin collections. Hence, maximal elimination of all gross disease is attempted in the treatment of PMP. However, PMP is progressive and recurrent. In this review, current chemotherapy for PMP and a number of experimental strategies for enhancement of microscopic cytoreduction are addressed.Expert opinion: According to the current standard of care, HIPEC is the chemotherapy of choice for patients with PMP, which is delivered after completion of CRS. This multimodal approach offers long-term benefits for selected patients. Nevertheless, HIPEC fails to maintain the surgical complete response achieved by CRS and needs to be supplemented by novel strategies. Given the role of mucin and mucin-secreting cells in the pathophysiology of PMP, locoregional use of safe agents capable of inducing cytotoxic effects on residual tumor cells and eliminating mucin is a promising avenue for further investigation.
    01/2015; 3(2). DOI:10.1517/21678707.2015.1006627
  • [Show abstract] [Hide abstract]
    ABSTRACT: Long-term glucocorticoid treatment induces central fat accumulation and metabolic dysfunction. We demonstrate that microRNA-27b plays a central role in the pathogenesis of glucocorticoid-induced central fat accumulation. Overexpression of miR-27b had the same effects as dexamethasone treatment in the inhibition of brown adipose differentiation and the energy expenditure of primary adipocyte. Conversely, antagonizing miR-27b function prevented dexamethasone suppression of the expression of BAT-specific genes. GCs transcriptionally regulate the miR-27b expression via a GR-mediated direct DNA binding mechanism, and miR-27b suppresses browning white adipose tissue by targeting the 3'UTR of Prdm16. In vivo, antagonizing miR-27b function in dexamethasone treated mice resulted in the efficient induction of brown adipocytes within white adipose tissue (WAT), improved GC-induced central fat accumulation. Collectively, our results indicate that miR-27b functions as a central target of glucocorticoid and as an upstream regulator of Prdm16 to control browning of WAT and consequently may represent a potential target in preventing obesity.
    Diabetes 09/2014; 64(2). DOI:10.2337/db14-0395 · 8.47 Impact Factor